IceCure Medical Projects Record Q4 2025 Sales Following FDA Approval of ProSense®

Icecure Medical ( (ICCM) ) has issued an announcement.

IceCure Medical announced its expectation to achieve record-breaking North American sales in the fourth quarter of 2025, boosted by the recent FDA approval of ProSense® for treating low-risk breast cancer in women aged 70 and above. The FDA authorization in October 2025 has led to a surge in demand, with influential U.S. hospital networks adopting the technology, underscoring the growing preference for minimally invasive cancer therapies and potentially expanding its market reach.

The most recent analyst rating on (ICCM) stock is a Hold with a $0.70 price target. To see the full list of analyst forecasts on Icecure Medical stock, see the ICCM Stock Forecast page.

Spark’s Take on ICCM Stock

According to Spark, TipRanks’ AI Analyst, ICCM is a Neutral.

Icecure Medical’s overall stock score is primarily impacted by its challenging financial performance, with persistent losses and negative cash flows. The technical analysis indicates a bearish trend, and valuation metrics are weak due to unprofitability. However, the positive sentiment from the earnings call, driven by FDA approval and strategic market opportunities, provides some optimism for future growth.

To see Spark’s full report on ICCM stock, click here.

More about Icecure Medical

IceCure Medical develops and markets innovative cryoablation systems using liquid-nitrogen technology for the minimally invasive destruction of tumors. Its flagship product, ProSense®, is used for treating benign and malignant tumors, with a focus on breast, kidney, bone, and lung cancer in key markets across the U.S., Europe, and Asia.

Average Trading Volume: 1,064,798

Technical Sentiment Signal: Sell

Current Market Cap: $42.98M

Find detailed analytics on ICCM stock on TipRanks’ Stock Analysis page.